



Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Date of this announcement

Friday December 03, 2021

The +securities the subject of this notification are:

☒ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
MYXAN	PERFORMANCE RIGHTS	6,573,802	03/12/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

3/12/2021



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

MYXAN : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

3/12/2021

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

☒ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

☒ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Scott Richards	Scott Richards	6,060,606

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

- Rights are eligible for vesting over a period of up to five years from the date of the grant, subject to achievement of specific vesting condition hurdles.
- 20% of the grant eligible for vesting 1 year after the base test date, 30% eligible for vesting 2 years after the base test date and the balance eligible for vesting 3 years after the base test date, subject to achievement of the vesting conditions.
- The number / proportion of Rights that vest is based on the absolute Total Shareholder Return (TSR) over the period with 20% vesting if a TSR Compound Annual Growth (CAGR) of 8% is achieved, rising to 100% vesting for achievement of a TSR CAGR of 15%.
- If CAGR performance conditions are met, vesting occurs progressively and at continuously increasing hurdles.
- For further information refer to the 2021 Annual Report - <https://www.maynepharmaceutical.com/investor-relations/results-report>

Any other information the entity wishes to provide about the +securities the subject of this notification

- The base test date for Rights is set as 1 September 2021 and the expiry date is 30 September 2026
- The Base Test Price for the Rights is \$0.33.
- If the Rights are not exercised before the expiry date they will automatically lapse.
- There are no voting rights or rights to dividends whilst the participant holds a Right.



Issue details

Number of +securities

6,573,802

For personal use only



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
MYX : ORDINARY FULLY PAID	1,764,840,757

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MYXAN : PERFORMANCE RIGHTS	64,235,260
MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	16,706,827



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

6,573,802

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No